Examkin

Question

Difficulty: HardInfectious Diseases

A 64-year-old man is evaluated in the intensive care unit for a persistent fever. He was admitted 8 days ago after a severe motor vehicle collision that resulted in multiple rib fractures, a pulmonary contusion, and a splenectomy. He has been mechanically ventilated since admission. Three days ago, he developed a temperature of 38.9°C (102.0°F), increased purulent endotracheal secretions, and increased oxygen requirements. A chest radiograph revealed a new right lower lobe consolidation. He was empirically started on intravenous cefepime, vancomycin, and amikacin. Today, his temperature is 37.4°C (99.3°F), and his oxygen requirements have decreased. The endotracheal aspirate culture from three days ago has grown Pseudomonas aeruginosa (>100,000 CFU/mL). Susceptibility testing shows the isolate is susceptible to cefepime, meropenem, piperacillin-tazobactam, and amikacin, but resistant to ciprofloxacin. No other organisms, including Staphylococcus aureus, have grown. Blood cultures obtained prior to antibiotic initiation are negative. Which of the following is the most appropriate next step in this patient's pharmacotherapy?

  1. Discontinue vancomycin and amikacin, and continue cefepimeAnswer
  2. B
    Discontinue vancomycin, and continue cefepime and amikacin
  3. C
    Discontinue amikacin, and continue cefepime and vancomycin
  4. D
    Continue cefepime, vancomycin, and amikacin
  5. E
    Discontinue current antibiotics, and initiate meropenem

Answer

The most appropriate next step is to discontinue vancomycin and amikacin, and continue therapy with cefepime alone.
The correct answer is to discontinue vancomycin and amikacin, and continue cefepime alone. This patient initially presented with ventilator-associated pneumonia (VAP) and appropriately received broad-spectrum empiric therapy targeting MRSA (vancomycin) and resistant Gram-negative organisms, including Pseudomonas (cefepime and amikacin). At 48 to 72 hours, when culture data return, therapy must be de-escalated. Because no MRSA was isolated, vancomycin can be safely discontinued. Furthermore, although empiric double antipseudomonal coverage is standard for critically ill patients at risk for multidrug-resistant organisms, definitive therapy should utilize a single active beta-lactam agent once susceptibilities are confirmed. Continuing an aminoglycoside like amikacin offers no survival benefit for definitive therapy and exposes the patient to nephrotoxicity and ototoxicity.

Step-by-Step Solution

1
Identify the patient's clinical diagnosis and indication for antibiotics.
The patient has ventilator-associated pneumonia (VAP) as evidenced by fever, purulent secretions, new lung consolidation, and positive respiratory cultures after >48 hours of mechanical ventilation.
Establishing the diagnosis determines the appropriate treatment guidelines to apply.
2
Analyze the culture and susceptibility results relative to the empiric antibiotic regimen.
Cultures grew only Pseudomonas aeruginosa susceptible to cefepime. Methicillin-resistant Staphylococcus aureus (MRSA) was not isolated.
Empiric therapy must be adjusted based on definitive microbiological data to prevent antibiotic resistance and drug toxicity.
3
Apply principles of antibiotic stewardship to de-escalate the regimen.
Vancomycin should be stopped because MRSA is absent. Amikacin should be stopped because combination therapy for Pseudomonas is only required empirically; definitive therapy requires only a single active beta-lactam agent (cefepime).
Guidelines recommend transitioning from broad-spectrum empiric therapy to targeted monotherapy once susceptibilities are known.

Key Concept

In the management of ventilator-associated pneumonia, empiric broad-spectrum therapy (e.g., MRSA coverage and double antipseudomonal coverage) should be promptly de-escalated to a single targeted agent once culture and susceptibility results are available and the patient is clinically improving.
Estimated Time:1m 30s
Rate this question

Topics

Infectious Diseases

More questions from this topic